The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance
Summary Objective Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atheroscle...
Saved in:
Published in | Clinical endocrinology (Oxford) Vol. 68; no. 5; pp. 716 - 723 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2008
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Objective Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent.
Patients and methods The study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha‐lipoic acid group and the placebo group). In the alpha‐lipoic acid group, 300 mg of alpha‐lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0·9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0·9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High‐resolution ultrasound was used to measure flow‐mediated endothelium‐dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)‐induced endothelium‐independent arterial dilation.
Results In the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha‐lipoic acid groups was significantly lower than in the controls (P < 0·01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (P > 0·05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (P < 0·01) and increased markedly from 60 to 120 min (P < 0·01). The alpha‐lipoic acid‐treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (P < 0·01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL‐C), lipoprotein (a) [Lp(a)], C‐reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (P < 0·01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (P < 0·01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha‐lipoic acid (P < 0·05), although the power of association decreased.
Conclusion In subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen‐derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia. |
---|---|
AbstractList | Objective
Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent.
Patients and methods
The study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha‐lipoic acid group and the placebo group). In the alpha‐lipoic acid group, 300 mg of alpha‐lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0·9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0·9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High‐resolution ultrasound was used to measure flow‐mediated endothelium‐dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)‐induced endothelium‐independent arterial dilation.
Results
In the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha‐lipoic acid groups was significantly lower than in the controls (
P <
0·01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (
P
> 0·05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (
P <
0·01) and increased markedly from 60 to 120 min (
P <
0·01). The alpha‐lipoic acid‐treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (
P <
0·01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL‐C), lipoprotein (a) [Lp(a)], C‐reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (
P <
0·01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (
P <
0·01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha‐lipoic acid (
P <
0·05), although the power of association decreased.
Conclusion
In subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen‐derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia. Summary Objective Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent. Patients and methods The study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha‐lipoic acid group and the placebo group). In the alpha‐lipoic acid group, 300 mg of alpha‐lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0·9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0·9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High‐resolution ultrasound was used to measure flow‐mediated endothelium‐dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)‐induced endothelium‐independent arterial dilation. Results In the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha‐lipoic acid groups was significantly lower than in the controls (P < 0·01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (P > 0·05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (P < 0·01) and increased markedly from 60 to 120 min (P < 0·01). The alpha‐lipoic acid‐treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (P < 0·01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL‐C), lipoprotein (a) [Lp(a)], C‐reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (P < 0·01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (P < 0·01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha‐lipoic acid (P < 0·05), although the power of association decreased. Conclusion In subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen‐derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia. Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent.OBJECTIVEImpaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent.The study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha-lipoic acid group and the placebo group). In the alpha-lipoic acid group, 300 mg of alpha-lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0.9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0.9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High-resolution ultrasound was used to measure flow-mediated endothelium-dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)-induced endothelium-independent arterial dilation.PATIENTS AND METHODSThe study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha-lipoic acid group and the placebo group). In the alpha-lipoic acid group, 300 mg of alpha-lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0.9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0.9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High-resolution ultrasound was used to measure flow-mediated endothelium-dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)-induced endothelium-independent arterial dilation.In the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha-lipoic acid groups was significantly lower than in the controls (P < 0.01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (P > 0.05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (P < 0.01) and increased markedly from 60 to 120 min (P < 0.01). The alpha-lipoic acid-treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (P < 0.01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL-C), lipoprotein (a) [Lp(a)], C-reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (P < 0.01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (P < 0.01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha-lipoic acid (P < 0.05), although the power of association decreased.RESULTSIn the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha-lipoic acid groups was significantly lower than in the controls (P < 0.01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (P > 0.05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (P < 0.01) and increased markedly from 60 to 120 min (P < 0.01). The alpha-lipoic acid-treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (P < 0.01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL-C), lipoprotein (a) [Lp(a)], C-reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (P < 0.01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (P < 0.01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha-lipoic acid (P < 0.05), although the power of association decreased.In subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen-derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia.CONCLUSIONIn subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen-derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia. Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the occurrence of cardiovascular disease. Endothelial dysfunction (ED) represents a very early step in the development of atherosclerosis. The aim of the present study was to examine ED in the fasting state and after a glucose challenge as well as after administration of an antioxidant agent. The study subjects included 42 IGT patients and 26 healthy individuals (control group). The IGT patients were randomly divided into two groups, 21 in each group (the alpha-lipoic acid group and the placebo group). In the alpha-lipoic acid group, 300 mg of alpha-lipoic acid was administrated before an oral glucose tolerance test (OGTT); in the placebo group, 250 ml of 0.9% sodium chloride was administrated before the OGTT. In addition, 250 ml of 0.9% sodium chloride was also administrated to the control subjects before the OGTT (control group), and then vascular function was examined in the fasting state and repeated 1 and 2 h after the glucose load. High-resolution ultrasound was used to measure flow-mediated endothelium-dependent arterial dilation (FMD) and glyceryltrinitrate (GTN)-induced endothelium-independent arterial dilation. In the fasting state, and at 60 and 120 min, FMD in both the placebo and alpha-lipoic acid groups was significantly lower than in the controls (P < 0.01). In the control group, FMD tended to decrease at 60 min after glucose loading and returned to the baseline levels at 120 min (P > 0.05). In the placebo group, FMD decreased significantly at 60 min after glucose loading (P < 0.01) and increased markedly from 60 to 120 min (P < 0.01). The alpha-lipoic acid-treated patients showed FMD values intermediate between the control subjects and the IGT patients treated with placebo, at both 60 and 120 min, and the differences were significant (P < 0.01). In multiple regression analysis, FMD was significantly correlated to fasting blood glucose (FBG), low density lipoprotein cholesterol (LDL-C), lipoprotein (a) [Lp(a)], C-reactive protein (CRP), thiobarbituric acid reactive substances (TBARS) and age in IGT patients at baseline (P < 0.01). Spearman's analysis showed a significant negative correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients (placebo group) (P < 0.01). There was also a significant correlation between FMD and plasma glucose levels, and between FMD and TBARS during the OGTT in IGT patients treated with alpha-lipoic acid (P < 0.05), although the power of association decreased. In subjects with IGT, FMD was impaired both in the fasting state and after a glucose challenge, probably through increased production of oxygen-derived free radicals. The ED observed after a glucose challenge is related to the extent of hyperglycaemia and TBARS, and an antioxidant agent can improve the impairment of endothelial function induced by acute hyperglycaemia. |
Author | Zhao, Lin-Shuang Sun, Hui-Ling Xiang, Guang-Da Yue, Ling Xu, Lin Hou, Jie |
Author_xml | – sequence: 1 givenname: Guang-Da surname: Xiang fullname: Xiang, Guang-Da organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China – sequence: 2 givenname: Hui-Ling surname: Sun fullname: Sun, Hui-Ling organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China – sequence: 3 givenname: Lin-Shuang surname: Zhao fullname: Zhao, Lin-Shuang organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China – sequence: 4 givenname: Jie surname: Hou fullname: Hou, Jie organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China – sequence: 5 givenname: Ling surname: Yue fullname: Yue, Ling organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China – sequence: 6 givenname: Lin surname: Xu fullname: Xu, Lin organization: Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, P. R. China |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20264607$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18070144$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc2O0zAUhS00iOkMvALyBnYpdlI7yQIkVA0dpKGzKT9iY93aN62Lm2TsBJp34KFxaOmCDViyrnX9nSNfnytyUTc1EkI5m_K4Xu2mPJMiSVMppilj-ZRlrCynh0dkcr64IJPYZQmTcnZJrkLYMcZEwfIn5JLHwvhsNiE_V1ukUHe2OVgTKwXXbiFxtm2spqCtoXbf-uY7Boq1abotOguOmiFUfa2jrqa2Nr1GQ9dDFPQd0u3Qot-4QQPuLVDTe1tv6P1itYrs6AfWR37jet0EpF3j0EOt8Sl5XIEL-OxUr8nHdzer-W1yd794P397l2jBeJmIrAK-zisJVQkGizRnuS6LtckAhVkXlZFcAOaSp6aYcSYxtkXcjBeGFWV2TV4efeNgDz2GTu1t0Ogc1Nj0QcmSMy4yEcHnJ7Bf79Go1ts9-EH9-b8IvDgBEDS4ahzDhjOXslTOJMsj9-bIad-E4LFS2nYw_l7nwTrFmRqDVTs15qfG_NQYrPodrDpEg-Ivg_Nb_i19fZT-sA6H_9ap-c1yPEV9ctTb0OHhrAf_Tck8y4X6vFyopfjCb-Wnr-pD9guPFsw- |
CODEN | CLECAP |
CitedBy_id | crossref_primary_10_1371_journal_pone_0115977 crossref_primary_10_1161_ATVBAHA_115_305530 crossref_primary_10_1016_j_mcna_2010_11_004 crossref_primary_10_1155_2013_849295 crossref_primary_10_3390_molecules28031043 crossref_primary_10_1016_j_ejps_2018_02_009 crossref_primary_10_1186_1475_2840_11_98 crossref_primary_10_1024_0300_9831_a000732 crossref_primary_10_1016_j_nutres_2012_08_002 crossref_primary_10_1080_19390211_2021_2020387 crossref_primary_10_1186_1475_2891_10_72 crossref_primary_10_1139_y11_072 crossref_primary_10_3390_ijms21197060 crossref_primary_10_1007_s12020_013_0095_8 crossref_primary_10_1080_10408398_2020_1861425 crossref_primary_10_1111_obr_12831 crossref_primary_10_1093_jn_nxab279 crossref_primary_10_3389_fimmu_2023_1127088 crossref_primary_10_3390_antiox9010082 crossref_primary_10_3389_fmed_2023_1168560 crossref_primary_10_3390_ijms151120169 crossref_primary_10_1007_s00394_020_02340_y crossref_primary_10_1152_ajpregu_00055_2020 crossref_primary_10_7762_cnr_2015_4_2_69 crossref_primary_10_3389_fphys_2018_00183 crossref_primary_10_1017_S0954422412000182 crossref_primary_10_1024_0300_9831_a000702 crossref_primary_10_1016_j_atherosclerosis_2014_12_028 crossref_primary_10_1111_j_1365_2362_2010_02424_x crossref_primary_10_1016_j_clnu_2017_06_002 crossref_primary_10_1272_jnms_80_200 crossref_primary_10_1016_j_ijcard_2009_09_539 crossref_primary_10_1016_j_metabol_2010_04_011 crossref_primary_10_3390_nu11020375 crossref_primary_10_1111_echo_12489 crossref_primary_10_1111_j_1365_2362_2009_02236_x crossref_primary_10_1155_2021_8852759 crossref_primary_10_1002_ptr_7406 crossref_primary_10_1186_s40662_020_00199_y crossref_primary_10_1016_j_clnesp_2019_03_015 crossref_primary_10_1108_NFS_03_2018_0082 crossref_primary_10_1002_ptr_6959 crossref_primary_10_3945_jn_111_144592 crossref_primary_10_4103_bbrj_bbrj_153_21 |
Cites_doi | 10.1001/archinte.161.3.397 10.1016/S0140-6736(97)90021-0 10.1161/01.ATV.20.3.823 10.2337/diacare.22.6.920 10.1016/S0735-1097(03)00994-X 10.2337/diacare.27.3.801 10.1007/s00125-001-0760-y 10.1152/ajpheart.1992.263.2.H321 10.1016/S0076-6879(78)52032-6 10.1111/j.1464-5491.2004.01109.x 10.2337/diacare.15.8.1020 10.1161/01.ATV.0000051384.43104.FC 10.1210/jcem.85.1.6258 10.1002/pro.5560070125 10.1161/01.CIR.0000028581.07992.56 10.1111/j.1365-2362.2005.01550.x 10.2337/db06-0231 10.1152/ajpcell.1996.271.5.C1424 10.1016/S0002-9343(96)00383-X 10.1016/S0002-9149(03)00611-8 10.1161/01.CIR.101.16.1899 10.1038/sj.ejcn.1600880 10.1016/S0735-1097(99)00168-0 10.1186/1475-2840-5-9 10.2337/diacare.25.8.1340 10.1038/320454a0 10.1002/biof.5520090216 10.2337/diacare.16.7.1022 10.1016/S0735-1097(98)00447-1 10.1161/01.RES.88.2.e14 10.1007/s00125-003-1060-5 10.1016/S0735-1097(00)00980-3 10.2337/diacare.18.8.1160 |
ContentType | Journal Article |
Copyright | 2007 The Authors 2008 INIST-CNRS |
Copyright_xml | – notice: 2007 The Authors – notice: 2008 INIST-CNRS |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1111/j.1365-2265.2007.03099.x |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2265 |
EndPage | 723 |
ExternalDocumentID | 18070144 20264607 10_1111_j_1365_2265_2007_03099_x CEN3099 ark_67375_WNG_N5X1H6VZ_M |
Genre | article Randomized Controlled Trial Journal Article Comparative Study |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 08P 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AAQQT AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K REN RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c5019-53fa1b7f6af9ade82707c98bd3ae5db8fd615ae7612d84106ee5d5e5d018d0893 |
IEDL.DBID | DR2 |
ISSN | 0300-0664 1365-2265 |
IngestDate | Fri Jul 11 03:24:01 EDT 2025 Thu Apr 03 07:05:50 EDT 2025 Mon Jul 21 09:10:34 EDT 2025 Tue Jul 01 01:32:40 EDT 2025 Thu Apr 24 23:13:25 EDT 2025 Wed Jan 22 16:59:22 EST 2025 Wed Oct 30 09:55:08 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Endocrinopathy Lipoic acid Improvement Dysfunction Acute Endothelial dysfunction Glucose tolerance test Antioxidant Impaired glucose tolerance Endocrinology Endothelium |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5019-53fa1b7f6af9ade82707c98bd3ae5db8fd615ae7612d84106ee5d5e5d018d0893 |
Notes | ark:/67375/WNG-N5X1H6VZ-M istex:4E5E3C8CE75B1071D893B5F6049B4932B5C1F3A1 ArticleID:CEN3099 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
PMID | 18070144 |
PQID | 69101535 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_69101535 pubmed_primary_18070144 pascalfrancis_primary_20264607 crossref_citationtrail_10_1111_j_1365_2265_2007_03099_x crossref_primary_10_1111_j_1365_2265_2007_03099_x wiley_primary_10_1111_j_1365_2265_2007_03099_x_CEN3099 istex_primary_ark_67375_WNG_N5X1H6VZ_M |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2008 |
PublicationDateYYYYMMDD | 2008-05-01 |
PublicationDate_xml | – month: 05 year: 2008 text: May 2008 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | Clinical endocrinology (Oxford) |
PublicationTitleAlternate | Clin Endocrinol (Oxf) |
PublicationYear | 2008 |
Publisher | Blackwell Publishing Ltd Blackwell |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
References | Ziegler, D., Nowak, H., Kempler, P., Vargha, P. & Low, P.A. (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine, 21, 114-121. Widlansky, M.E., Gocke, N., Keaney, J.F. & Vita, J.A. (2003) The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology, 42, 1149-1160. Buege, J.A. & Aust, S.D. (1987) Microsomal lipid peroxidation. Methods in Enzymology, 52, 302-310. Schaechinger, V., Britten, M.B. & Zeiher, A.M. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 101, 1899-1906. Kuller, L.H., Velentgas, P., Barzilay, J., Beauchanp, N.J., Oleary, D.H. & Savage, P.J. (2000) Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 823-829. Nathan, D.M., Meigs, J.B. & Singer, D.E. (1997) The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is or is it? Lancet, 350, SI4-S19. Kawano, H., Motoyama, T., Hirashima, O., Nobutaka, H., Miyao, Y., Salamoto, T., Kugiyama, K., Ogawa, H. & Yasue, H. (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. Journal of the American College of Cardiology, 34, 146-154. Wingard, D.L., Barrett-Connor, E.L., Scheidt-Nave, C. & McPhillips, J.B. (1993) Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. Diabetes Care, 16, 1022-1025. Paolisso, G., Tagliamonte, M.R., Barbieri, M., Zito, G.A., Gambardella, A., Varricchio, G., Ragno, E. & Varricchio, M. (2000) Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. Journal of Clinical Endocrinology and Metabolism, 85, 109-115. Beckman, J.S. & Koppenol, W.H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. American Journal of Physiology, 271, C1424-C1437. Tesfamariam, B. & Cohen, R.A. (1992) Free radicals mediate endothelial cell dysfunction caused by elevated glucose. American Journal of Physiology, 263, H321-H326. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M., Thaiss, F., Stahl, R.A., Warnholtz, A., Meinertz, T., Griendling, K., Harrison, D.G., Forstemann, U. & Munzel, T. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation Research, 88, 14-22. Xiang, G.D. & Wu, Y.H. (2003) Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 46, 514-519. Title, L.M., Cummings, P.M., Giddens, K. & Nassar, B.A. (2000) Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamin C and E. Journal of the American College of Cardiology, 36, 2185-2191. Nagamastsu, M., Nickander, K.K., Schmelzer, J.D., Ray, A., Wittrock, D.A., Tritschler, H. & Low, P.A. (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care, 18, 1160-1167. Schmoelzer, I. & Wascher, T.C. (2006) Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovascular Diabetology, 5, 9-12. Moncada, S., Palmer, R.M.J. & Higgs, E.A. (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews, 43, 109-142. Meigs, J.B., Singer, D.E., Sullivan, L.M., Dukes, KA, D'Agostino, R.B., Nathan, D.M., Wager, E.H., Kaplan, S.H. & Greenfield, S. (1997) Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). The NIDDM Patients Outcome Research Team. American Journal of Medicine, 102, 38-47. Thomas, S.R., Witting, P.K. & Stocker, R. (1999) A role for reduced coenzyme Q in atherosclerosis? Biofactors, 9, 207-224. The DECODE study: Group for the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and two hour diagnostic criteria. Archives of Internal Medicine, 161, 397-405. Motoyama, T., Kawano, H., Kugiyama, K., Hirashima, O., Ohgushi, M., Tsunoda, R., Moriyama, Y., Miyao, Y., Yoshimura, M., Ogawa, H. & Yasue, H. (1998) Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. Journal of the American College of Cardiology, 32, 1672-1679. Mykkänen, L., Laakso, M. & Pyörälä, K. (1992) Asymptomatic hyperglycemia and atherosclerosic vascular disease in the elderly. Diabetes Care, 15, 1020-1030. Rubanyi, G.M. & Vanhoutte, P.M. (1986) Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. American Journal of Physiology, 250, H815-H821. Gryglewski, R.J., Palmer, R.M.J. & Moncada, S. (1986) Superoxide anion is involved in the breakdown of endothelium-dependent vascular relaxing factor. Nature, 320, 454-456. Reed, L.J. (1998) From lipoic acid to multi-enzyme complexes. Protein Science, 7, 220-224. Leurs, P.B., Oerle, R.V., Stolk, R.P., Grobbee, D.E., Hamulyak, K. & Wolffenbuttel, B.H.R. (2002) Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care, 25, 1340-1345. Vital, J.A. & Keaney, J.F. (2002) Endothelial function: a barometer for cardiovascular risk. Circulation, 106, 640-642. Hsueh, W.A. & Quinones, M.J. (2003) Role of endothelial dysfunction in insulin resistance. American Journal of Cardiology, 92, 10-71. Xiang, G.D. & Wang, Y.L. (2004) Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 27, 801-802. Tominaga, M., Eguchi, H., Igarashi, K., Kato, T. & Sekikawa, A. (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care, 22, 920-924. Xiang, G.D., Xu, L., Zhao, L.S., Yue, L. & Hou, J. (2006) The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 55, 2126-2131. Overvad, K., Diamant, B., Holm, L., Holmer, G., Mortensen, S.A. & Stender, S. (1999) Coenzyme Q10 in health and disease. European Journal of Clinical Nutrition, 53, 764-770. Boneti, P.O., Lerman, L.O. & Lerman, A. (2003) Endothelial dysfunction, a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 168-175. Watts, G.F., Playford, D.A., Croft, K.D., Ward, N.C., Mori, T.A. & Burke, V. (2002) Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia, 45, 420-426. Wascher, T.C., Schmoelzer, I., Wiegratz, A., Stuehlinger, M., Mueller-Wieland, D., Kotzka, J. & Enderle, M. (2005) Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. European Journal of Clinical Investigation, 35, 551-557. 2004; 21 2001; 161 1987; 52 1992; 263 2004; 27 2006; 55 1997; 350 2000; 85 2000; 20 1986; 250 2006; 5 1999; 22 1995 1992; 15 1995; 18 2001; 88 1999; 9 1997; 102 2002; 25 1993; 16 2003; 92 2000; 36 1991; 43 1986; 320 2002; 45 2003; 46 2002; 106 1999; 34 1996; 271 1999; 53 2000; 101 1998; 7 1998; 32 2003; 42 2005; 35 2003; 23 e_1_2_5_26_2 e_1_2_5_24_2 e_1_2_5_22_2 Xiang G.D. (e_1_2_5_14_2) 2003; 46 e_1_2_5_23_2 e_1_2_5_21_2 e_1_2_5_29_2 Vital J.A. (e_1_2_5_20_2) 2002; 106 Rubanyi G.M. (e_1_2_5_27_2) 1986; 250 e_1_2_5_37_2 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 Packer L. (e_1_2_5_11_2) 1995 e_1_2_5_17_2 e_1_2_5_19_2 e_1_2_5_30_2 Moncada S. (e_1_2_5_25_2) 1991; 43 Paolisso G. (e_1_2_5_28_2) 2000; 85 |
References_xml | – reference: Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M., Thaiss, F., Stahl, R.A., Warnholtz, A., Meinertz, T., Griendling, K., Harrison, D.G., Forstemann, U. & Munzel, T. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation Research, 88, 14-22. – reference: Title, L.M., Cummings, P.M., Giddens, K. & Nassar, B.A. (2000) Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamin C and E. Journal of the American College of Cardiology, 36, 2185-2191. – reference: Xiang, G.D., Xu, L., Zhao, L.S., Yue, L. & Hou, J. (2006) The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 55, 2126-2131. – reference: Schaechinger, V., Britten, M.B. & Zeiher, A.M. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 101, 1899-1906. – reference: Gryglewski, R.J., Palmer, R.M.J. & Moncada, S. (1986) Superoxide anion is involved in the breakdown of endothelium-dependent vascular relaxing factor. Nature, 320, 454-456. – reference: Buege, J.A. & Aust, S.D. (1987) Microsomal lipid peroxidation. Methods in Enzymology, 52, 302-310. – reference: Xiang, G.D. & Wang, Y.L. (2004) Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 27, 801-802. – reference: Wingard, D.L., Barrett-Connor, E.L., Scheidt-Nave, C. & McPhillips, J.B. (1993) Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. Diabetes Care, 16, 1022-1025. – reference: Moncada, S., Palmer, R.M.J. & Higgs, E.A. (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews, 43, 109-142. – reference: Paolisso, G., Tagliamonte, M.R., Barbieri, M., Zito, G.A., Gambardella, A., Varricchio, G., Ragno, E. & Varricchio, M. (2000) Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. Journal of Clinical Endocrinology and Metabolism, 85, 109-115. – reference: Vital, J.A. & Keaney, J.F. (2002) Endothelial function: a barometer for cardiovascular risk. Circulation, 106, 640-642. – reference: The DECODE study: Group for the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and two hour diagnostic criteria. Archives of Internal Medicine, 161, 397-405. – reference: Meigs, J.B., Singer, D.E., Sullivan, L.M., Dukes, KA, D'Agostino, R.B., Nathan, D.M., Wager, E.H., Kaplan, S.H. & Greenfield, S. (1997) Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). The NIDDM Patients Outcome Research Team. American Journal of Medicine, 102, 38-47. – reference: Watts, G.F., Playford, D.A., Croft, K.D., Ward, N.C., Mori, T.A. & Burke, V. (2002) Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia, 45, 420-426. – reference: Kawano, H., Motoyama, T., Hirashima, O., Nobutaka, H., Miyao, Y., Salamoto, T., Kugiyama, K., Ogawa, H. & Yasue, H. (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. Journal of the American College of Cardiology, 34, 146-154. – reference: Overvad, K., Diamant, B., Holm, L., Holmer, G., Mortensen, S.A. & Stender, S. (1999) Coenzyme Q10 in health and disease. European Journal of Clinical Nutrition, 53, 764-770. – reference: Kuller, L.H., Velentgas, P., Barzilay, J., Beauchanp, N.J., Oleary, D.H. & Savage, P.J. (2000) Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 823-829. – reference: Motoyama, T., Kawano, H., Kugiyama, K., Hirashima, O., Ohgushi, M., Tsunoda, R., Moriyama, Y., Miyao, Y., Yoshimura, M., Ogawa, H. & Yasue, H. (1998) Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. Journal of the American College of Cardiology, 32, 1672-1679. – reference: Widlansky, M.E., Gocke, N., Keaney, J.F. & Vita, J.A. (2003) The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology, 42, 1149-1160. – reference: Nathan, D.M., Meigs, J.B. & Singer, D.E. (1997) The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is or is it? Lancet, 350, SI4-S19. – reference: Mykkänen, L., Laakso, M. & Pyörälä, K. (1992) Asymptomatic hyperglycemia and atherosclerosic vascular disease in the elderly. Diabetes Care, 15, 1020-1030. – reference: Reed, L.J. (1998) From lipoic acid to multi-enzyme complexes. Protein Science, 7, 220-224. – reference: Tominaga, M., Eguchi, H., Igarashi, K., Kato, T. & Sekikawa, A. (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care, 22, 920-924. – reference: Hsueh, W.A. & Quinones, M.J. (2003) Role of endothelial dysfunction in insulin resistance. American Journal of Cardiology, 92, 10-71. – reference: Xiang, G.D. & Wu, Y.H. (2003) Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 46, 514-519. – reference: Beckman, J.S. & Koppenol, W.H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. American Journal of Physiology, 271, C1424-C1437. – reference: Wascher, T.C., Schmoelzer, I., Wiegratz, A., Stuehlinger, M., Mueller-Wieland, D., Kotzka, J. & Enderle, M. (2005) Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. European Journal of Clinical Investigation, 35, 551-557. – reference: Tesfamariam, B. & Cohen, R.A. (1992) Free radicals mediate endothelial cell dysfunction caused by elevated glucose. American Journal of Physiology, 263, H321-H326. – reference: Rubanyi, G.M. & Vanhoutte, P.M. (1986) Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. American Journal of Physiology, 250, H815-H821. – reference: Thomas, S.R., Witting, P.K. & Stocker, R. (1999) A role for reduced coenzyme Q in atherosclerosis? Biofactors, 9, 207-224. – reference: Nagamastsu, M., Nickander, K.K., Schmelzer, J.D., Ray, A., Wittrock, D.A., Tritschler, H. & Low, P.A. (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care, 18, 1160-1167. – reference: Ziegler, D., Nowak, H., Kempler, P., Vargha, P. & Low, P.A. (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine, 21, 114-121. – reference: Leurs, P.B., Oerle, R.V., Stolk, R.P., Grobbee, D.E., Hamulyak, K. & Wolffenbuttel, B.H.R. (2002) Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care, 25, 1340-1345. – reference: Boneti, P.O., Lerman, L.O. & Lerman, A. (2003) Endothelial dysfunction, a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 168-175. – reference: Schmoelzer, I. & Wascher, T.C. (2006) Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovascular Diabetology, 5, 9-12. – volume: 35 start-page: 551 year: 2005 end-page: 557 article-title: Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance publication-title: European Journal of Clinical Investigation – volume: 52 start-page: 302 year: 1987 end-page: 310 article-title: Microsomal lipid peroxidation publication-title: Methods in Enzymology – volume: 16 start-page: 1022 year: 1993 end-page: 1025 article-title: Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM publication-title: Diabetes Care – volume: 102 start-page: 38 year: 1997 end-page: 47 article-title: Metabolic control and prevalent cardiovascular disease in non‐insulin‐dependent diabetes mellitus (NIDDM). The NIDDM Patients Outcome Research Team publication-title: American Journal of Medicine – volume: 271 start-page: C1424 year: 1996 end-page: C1437 article-title: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly publication-title: American Journal of Physiology – volume: 46 start-page: 514 year: 2003 end-page: 519 article-title: Apolipoprotein e4 allele and endothelium‐dependent arterial dilation in type 2 diabetes mellitus without angiopathy publication-title: Diabetologia – volume: 55 start-page: 2126 year: 2006 end-page: 2131 article-title: The relationship between plasma osteoprotegerin and endothelium‐dependent arterial dilation in type 2 diabetes publication-title: Diabetes – volume: 45 start-page: 420 year: 2002 end-page: 426 article-title: Coenzyme Q improves endothelial dysfunction of the brachial artery in type II diabetes mellitus publication-title: Diabetologia – start-page: 545 year: 1995 end-page: 591 – volume: 250 start-page: H815 year: 1986 end-page: H821 article-title: Oxygen‐derived free radicals, endothelium, and responsiveness of vascular smooth muscle publication-title: American Journal of Physiology – volume: 101 start-page: 1899 year: 2000 end-page: 1906 article-title: Prognostic impact of coronary vasodilator dysfunction on adverse long‐term outcome of coronary heart disease publication-title: Circulation – volume: 5 start-page: 9 year: 2006 end-page: 12 article-title: Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance publication-title: Cardiovascular Diabetology – volume: 161 start-page: 397 year: 2001 end-page: 405 article-title: Glucose tolerance and cardiovascular mortality: comparison of fasting and two hour diagnostic criteria publication-title: Archives of Internal Medicine – volume: 27 start-page: 801 year: 2004 end-page: 802 article-title: Regular aerobic exercise training improves endothelium‐dependent artery dilation in patients with impaired fasting glucose publication-title: Diabetes Care – volume: 23 start-page: 168 year: 2003 end-page: 175 article-title: Endothelial dysfunction, a marker of atherosclerotic risk publication-title: Arteriosclerosis, Thrombosis and Vascular Biology – volume: 20 start-page: 823 year: 2000 end-page: 829 article-title: Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all‐cause mortality publication-title: Arteriosclerosis, Thrombosis and Vascular Biology – volume: 18 start-page: 1160 year: 1995 end-page: 1167 article-title: Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy publication-title: Diabetes Care – volume: 43 start-page: 109 year: 1991 end-page: 142 article-title: Nitric oxide: physiology, pathophysiology, and pharmacology publication-title: Pharmacological Reviews – volume: 42 start-page: 1149 year: 2003 end-page: 1160 article-title: The clinical implications of endothelial dysfunction publication-title: Journal of the American College of Cardiology – volume: 9 start-page: 207 year: 1999 end-page: 224 article-title: A role for reduced coenzyme Q in atherosclerosis? publication-title: Biofactors – volume: 92 start-page: 10 year: 2003 end-page: 71 article-title: Role of endothelial dysfunction in insulin resistance publication-title: American Journal of Cardiology – volume: 25 start-page: 1340 year: 2002 end-page: 1345 article-title: Tissue factor pathway inhibitor and other endothelium‐dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes publication-title: Diabetes Care – volume: 320 start-page: 454 year: 1986 end-page: 456 article-title: Superoxide anion is involved in the breakdown of endothelium‐dependent vascular relaxing factor publication-title: Nature – volume: 22 start-page: 920 year: 1999 end-page: 924 article-title: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study publication-title: Diabetes Care – volume: 7 start-page: 220 year: 1998 end-page: 224 article-title: From lipoic acid to multi‐enzyme complexes publication-title: Protein Science – volume: 88 start-page: 14 year: 2001 end-page: 22 article-title: Mechanisms underlying endothelial dysfunction in diabetes mellitus publication-title: Circulation Research – volume: 21 start-page: 114 year: 2004 end-page: 121 article-title: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha‐lipoic acid: a meta‐analysis publication-title: Diabetic Medicine – volume: 36 start-page: 2185 year: 2000 end-page: 2191 article-title: Oral glucose loading acutely attenuates endothelium‐dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamin C and E publication-title: Journal of the American College of Cardiology – volume: 263 start-page: H321 year: 1992 end-page: H326 article-title: Free radicals mediate endothelial cell dysfunction caused by elevated glucose publication-title: American Journal of Physiology – volume: 350 start-page: SI4 year: 1997 end-page: S19 article-title: The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is or is it? publication-title: Lancet – volume: 32 start-page: 1672 year: 1998 end-page: 1679 article-title: Vitamin E administration improves impairment of endothelium‐dependent vasodilation in patients with coronary spastic angina publication-title: Journal of the American College of Cardiology – volume: 15 start-page: 1020 year: 1992 end-page: 1030 article-title: Asymptomatic hyperglycemia and atherosclerosic vascular disease in the elderly publication-title: Diabetes Care – volume: 85 start-page: 109 year: 2000 end-page: 115 article-title: Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 106 start-page: 640 year: 2002 end-page: 642 article-title: Endothelial function: a barometer for cardiovascular risk publication-title: Circulation – volume: 53 start-page: 764 year: 1999 end-page: 770 article-title: Coenzyme Q in health and disease publication-title: European Journal of Clinical Nutrition – volume: 34 start-page: 146 year: 1999 end-page: 154 article-title: Hyperglycemia rapidly suppresses flow‐mediated endothelium‐dependent vasodilation of brachial artery publication-title: Journal of the American College of Cardiology – ident: e_1_2_5_19_2 doi: 10.1001/archinte.161.3.397 – ident: e_1_2_5_23_2 doi: 10.1016/S0140-6736(97)90021-0 – ident: e_1_2_5_18_2 doi: 10.1161/01.ATV.20.3.823 – ident: e_1_2_5_17_2 doi: 10.2337/diacare.22.6.920 – ident: e_1_2_5_21_2 doi: 10.1016/S0735-1097(03)00994-X – volume: 250 start-page: H815 year: 1986 ident: e_1_2_5_27_2 article-title: Oxygen‐derived free radicals, endothelium, and responsiveness of vascular smooth muscle publication-title: American Journal of Physiology – ident: e_1_2_5_15_2 doi: 10.2337/diacare.27.3.801 – ident: e_1_2_5_32_2 doi: 10.1007/s00125-001-0760-y – ident: e_1_2_5_36_2 doi: 10.1152/ajpheart.1992.263.2.H321 – ident: e_1_2_5_13_2 doi: 10.1016/S0076-6879(78)52032-6 – ident: e_1_2_5_34_2 doi: 10.1111/j.1464-5491.2004.01109.x – ident: e_1_2_5_2_2 doi: 10.2337/diacare.15.8.1020 – ident: e_1_2_5_4_2 doi: 10.1161/01.ATV.0000051384.43104.FC – volume: 85 start-page: 109 year: 2000 ident: e_1_2_5_28_2 article-title: Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients publication-title: Journal of Clinical Endocrinology and Metabolism doi: 10.1210/jcem.85.1.6258 – ident: e_1_2_5_33_2 doi: 10.1002/pro.5560070125 – volume: 106 start-page: 640 year: 2002 ident: e_1_2_5_20_2 article-title: Endothelial function: a barometer for cardiovascular risk publication-title: Circulation doi: 10.1161/01.CIR.0000028581.07992.56 – ident: e_1_2_5_9_2 doi: 10.1111/j.1365-2362.2005.01550.x – ident: e_1_2_5_16_2 doi: 10.2337/db06-0231 – ident: e_1_2_5_35_2 doi: 10.1152/ajpcell.1996.271.5.C1424 – start-page: 545 volume-title: Handbook of Antioxidants year: 1995 ident: e_1_2_5_11_2 – ident: e_1_2_5_24_2 doi: 10.1016/S0002-9343(96)00383-X – ident: e_1_2_5_37_2 doi: 10.1016/S0002-9149(03)00611-8 – ident: e_1_2_5_5_2 doi: 10.1161/01.CIR.101.16.1899 – ident: e_1_2_5_30_2 doi: 10.1038/sj.ejcn.1600880 – ident: e_1_2_5_7_2 doi: 10.1016/S0735-1097(99)00168-0 – ident: e_1_2_5_8_2 doi: 10.1186/1475-2840-5-9 – ident: e_1_2_5_22_2 doi: 10.2337/diacare.25.8.1340 – volume: 43 start-page: 109 year: 1991 ident: e_1_2_5_25_2 article-title: Nitric oxide: physiology, pathophysiology, and pharmacology publication-title: Pharmacological Reviews – ident: e_1_2_5_26_2 doi: 10.1038/320454a0 – ident: e_1_2_5_31_2 doi: 10.1002/biof.5520090216 – ident: e_1_2_5_3_2 doi: 10.2337/diacare.16.7.1022 – ident: e_1_2_5_12_2 doi: 10.1016/S0735-1097(98)00447-1 – ident: e_1_2_5_6_2 doi: 10.1161/01.RES.88.2.e14 – volume: 46 start-page: 514 year: 2003 ident: e_1_2_5_14_2 article-title: Apolipoprotein e4 allele and endothelium‐dependent arterial dilation in type 2 diabetes mellitus without angiopathy publication-title: Diabetologia doi: 10.1007/s00125-003-1060-5 – ident: e_1_2_5_29_2 doi: 10.1016/S0735-1097(00)00980-3 – ident: e_1_2_5_10_2 doi: 10.2337/diacare.18.8.1160 |
SSID | ssj0005807 |
Score | 2.1204867 |
Snippet | Summary
Objective Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently... Objective Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with... Impaired glucose tolerance (IGT) is considered a transitional phase in the development of type 2 diabetes, and is also independently associated with the... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 716 |
SubjectTerms | Adult Antioxidants - pharmacology Biological and medical sciences Blood Glucose Case-Control Studies Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Free Radicals Fundamental and applied biological sciences. Psychology Glucose Tolerance Test Humans Hyperglycemia - complications Male Medical sciences Middle Aged Thioctic Acid - pharmacology Vertebrates: endocrinology |
Title | The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance |
URI | https://api.istex.fr/ark:/67375/WNG-N5X1H6VZ-M/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2265.2007.03099.x https://www.ncbi.nlm.nih.gov/pubmed/18070144 https://www.proquest.com/docview/69101535 |
Volume | 68 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9swEBZlC6WXvh_uY6tD6c0hjmXZPpZld0MhKZRsG3oRY0numrjOEjuQ9NRfUPob-0s6IzvZuuxhKT2EBCdj5Mk30jf2NyPGXkspdJIGiR8jn_eFgNhPjTZ-ENo0oVbVxtVxT6ZyfCbezaN5p3-iWpi2P8T-hhtFhpuvKcAhq_tB7hRaIxl1nQhDZDsD4pP0BfGjD5edpKKucjqkQmocYF_Uc-WJeivVTXL6hpSTUKPz8nbXi6toaZ_lumXq5C5b7C6wVacsBusmG-hvf_V-_D8euMfudGyWv23hd5_dsNUDdmvSPa9_yH4gCjmQoHJTGHznrrT31_efZXGxLDQHXRheuPsatua2MlQPVmJIcLOtackl2PCiMghAw7MtGqwby88xeV59Kbca7NcCeFtqyd-fzmb4Wzof4ERueCfH582ytORJ-4idnRzPjsZ-twOEryPknn4U5hBkcS4hT8HYZBQPY50mmQnBRiZLcoOEDGyMNA0xhdmtxcMRvoZBYoZIxR6zg2pZ2aeMJwDa6FzLTAuRBZBoYUGKIAERBNrGHot3_7bSXXt02qWjVH-kSehuRe6mzTtj5dytNh4L9pYXbYuQa9i8cYDaG8BqQRK7OFKfpqdqGs2Dsfz4WU08dthD3N5ghMmzkEMc96sdBBXODPS4Byq7XNdKIhPE9Szy2JMWmZejw2CgTNpj0uHr2sNWR8dT-vTsXw2fs9ut4IYUoy_YQbNa25fI6prs0MXrb_uoP5g |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hVgIuvB_m0e4BcXMUx_twjqhqG6AxEkoh4rJa767BqnGqxJESTvwCxG_klzCzdlKMeqgQBytWlLHWk292v9mdByEvhGAmGUZJKIHPh4xpGQ6tsWEUu2GCpaqtz-Mep2J0yt5M-bRtB4S5ME19iO2GG1qGn6_RwHFDumvlPkRrIHhbijAGutMDQrmLDb69f_X-opYUb3OnY0ylhiF2w3oufVJnrdpFta8wdlIvQH150_fiMmLa5bl-oTq6TcrNKzbxKWe9ZZ31zLe_qj_-Jx3cIbdaQktfNQi8S6656h65Pm6P7O-THwBEqjGmclVY-KQ-u_fX959lcT4rDNWmsLTwWxtuQV1lMSWsBKugdr3AVReRQ4vKAgYtzdYgsKwd_QL-8_xzuTbafS00bbIt6bvjyQR-i8_TMJdb2kbk03pWOlSle0BOjw4nB6OwbQIRGg70M-RxrqNM5kLnQ21dMpB9aYZJZmPtuM2S3AIn004CUwNYgYPr4GsOVz9KbB_Y2EOyU80q95jQRGtjTW5EZhjLIp0Y5rRgUaJZFBknAyI3f7cybYV0bNRRqj88JVC3QnVj_06pvLrVKiDRVvK8qRJyBZmXHlFbAT0_wyg7ydXH9FilfBqNxIdPahyQvQ7ktgID8J-Z6MO49zcYVDA54ImPrtxsuVACyCAsaTwgjxpoXowOrAGd6YAID7ArD1sdHKZ49-RfBffJjdFkfKJOXqdvn5KbTfwNBpA-Izv1fOmeA8mrsz1vvL8B3YdDsw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQrrTiwvsRHrs-IG6pmsaxnSPa3W55tCDUhYqL5dgORA1p1aZSy4lfgPiN_BJmkrRL0B5WiEOVqspEzvQb-5vkmzEhzzhnRsaB9AXweZ8xLfzYGusHoYsltqq2VR33cMQH5-zVJJo0-ieshan7Q-weuGFkVPM1Bvjcpu0grxRaPR41nQhDYDsd4JP7jHclIvzk_UUrqagpnQ6xkhpG2Fb1XHql1lK1j15fo3RSL8F7ab3txWW8tE1zq3Wqf5NMt3dYy1OmnVWZdMy3v5o__h8X3CI3GjpLX9T4u02uueIOORg2L-zvkh8AQ6pRUbnOLBxpVdv76_vPPJvPMkO1ySzNqgcbbkldYbEgLIeYoHazxDUXcUOzwgICLU02YLAqHf0C2fPic74x2n3NNK1rLenbs_EYzsXraZjJLW30-LSc5Q496e6R8_7p-HjgN1tA-CYC8ulHYaqDRKRcp7G2TvZEV5hYJjbULrKJTC0wMu0E8DQAFaS3Dn6O4NMNpAUQhPfJXjEr3ENCpdbGmtTwxDCWBFoa5jRngdQsCIwTHhHbf1uZpj86btORqz_yJHC3Qnfj7p1CVe5Wa48EO8t53SPkCjbPK0DtDPRiiho7EamPozM1iibBgH_4pIYeOWwhbmfQg-wZgA7jPtpCUMHUgO97dOFmq6XiQAVhQYs88qBG5sXoIBgwlfYIr_B15WGr49MRfnv0r4ZH5ODdSV-9eTl6_Zhcr8U3qB59QvbKxco9BYZXJodV6P4G9IZCaw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+antioxidant+alpha%E2%80%90lipoic+acid+improves+endothelial+dysfunction+induced+by+acute+hyperglycaemia+during+OGTT+in+impaired+glucose+tolerance&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Xiang%2C+Guang%E2%80%90Da&rft.au=Sun%2C+Hui%E2%80%90Ling&rft.au=Zhao%2C+Lin%E2%80%90Shuang&rft.au=Hou%2C+Jie&rft.date=2008-05-01&rft.issn=0300-0664&rft.eissn=1365-2265&rft.volume=68&rft.issue=5&rft.spage=716&rft.epage=723&rft_id=info:doi/10.1111%2Fj.1365-2265.2007.03099.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1365_2265_2007_03099_x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon |